sudok1 / iStockphoto.com
The Patent Trial and Appeal Board (PTAB) has upheld a Research Corporation Technologies patent for anti-epileptic drug Vimpat (lacosamide) in a case brought by Argentum Pharmaceuticals.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
PTAB, USPTO, epileptic, patent, IPR, Mylan, Research Corporation Technologies, Argentum Pharmaceuticals